Loading…
CLYM
Climb Bio, Inc.
NASDAQ· Healthcare· Biotechnology
$14.57-3.25%
Key metrics
- Market cap
- $836.85M
- P/E
- —
- Forward P/E
- —
- P/B
- 3.5x
- Dividend yield
- —
- EPS
- -$0.82
- ROE
- -27.10%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.08
- 52-week high
- $18.33
- 52-week low
- $1.54
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
- 28
- Wellesley Hills, United States
Company description provided by Yahoo Finance.